Day 3 Program

General Session 2

Day 3: December 11, 2025

9:00 AM–12:00 PM CST

Hall 1

Session Details

The text of the abstracts will be posted on Monday, November 24.

Moderator

Wendy Woodward, MD Anderson Cancer Center, Houston, TX

Moderator

Francois-Clement Bidard, Institut Curie, Paris, France

GS2-01

More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy – primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R)study

Thorsten Kühn, Die Filderklinik gGmbH / University of Ulm, Ulm, Germany

GS2-02

Axillary surgery in breast cancer patients with one to three sentinel node macrometastases and breast-conserving therapy: Secondary results of the INSEMA trial

Toralf Reimer, University of Rostock, Rostock, Germany

GS2-03

Insights of applied radiotherapy among patients undergoing breast-conserving surgery with or without axillary sentinel lymph node biopsy: secondary results from the INSEMA trial

Guido Hildebrandt, University Medicine Rostock, Rostock, Germany

GS2-04

Heating up cold tumors: single-cell mapping of immune and adenosine pathway reprogramming in luminal B breast cancer (Neo-CheckRay trial)

Marcela Carausu, Institut Jules Bordet, Brussels, Belgium

GS2-05

Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Gaorav Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

GS2-06

Discussant for GS2-05

Stephen Shiao

GS2-07

Effect of Preoperative Breast MRI Staging on Local Regional Recurrence (LRR) in Early Stage Breast cancer: Alliance A011104/ACRIN 6694

Isabelle Bedrosian, University of Texas MD Anderson Cancer Center, Houston, TX

GS2-08

Discussant for GS2-07

Bruce Mann, Royal Melbourne Hospital, Melbourne, Australia

GS2-09

The single-arm confirmatory trial of tamoxifen alone without surgery for low-risk DCIS of the breast with ER-positive HER2-negative (LORETTA trial: JCOG1505)

Hiroji Iwata, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

GS2-10

Discussant for GS2-09

Eric P. Winer, Yale Cancer Center, New Haven, CT

GS2-11

Omission of sentinel lymph node biopsy in clinically T1-2 node-negative breast cancer patients treated with breast-conserving therapy: results of the Dutch BOOG 2013-08 randomized controlled trial after a median follow-up of 5 years

M. L. Smidt, Maastricht University Medical Center+, Maastricht, Netherlands

GS2-12

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): final 10-year analysis of a randomised, factorial, multicentre, open-label, phase 3 study

Boon H Chua, University of New South Wales, Sydney, Australia